Antibiotic Treatment for Diabetic Patients with Paronychia

Introduction to Antibiotic Treatment

The American College of Physicians recommends that for a diabetic patient with paronychia, drainage is the primary treatment, and antibiotics are only indicated if there is significant surrounding cellulitis, systemic signs of infection, or the patient has risk factors for complications—in which case, oral clindamycin 300-450 mg three times daily or amoxicillin-clavulanate 875 mg twice daily for 7-10 days is recommended 1

The Infectious Diseases Society of America recommends clindamycin 300-450 mg orally three times daily as a first-line option, providing excellent coverage against gram-positive cocci including community-associated MRSA 2
The American Academy of Dermatology suggests amoxicillin-clavulanate 875 mg orally twice daily as another first-line option, offering broad-spectrum coverage against S. aureus, streptococci, and anaerobes 2, 3
Dicloxacillin 500 mg orally four times daily is recommended for methicillin-susceptible S. aureus 3
Cephalexin 500 mg orally four times daily is another beta-lactam option 2

The Centers for Disease Control and Prevention recommend a duration of therapy of 7-10 days for uncomplicated cases with cellulitis, and up to 14 days if extensive cellulitis or slow clinical response 2, 3
The American Diabetes Association emphasizes the importance of optimizing glycemic control, as hyperglycemia impairs infection eradication and wound healing 2, 4
The British Association of Dermatologists highlights the need to evaluate for underlying onychomycosis, which is highly prevalent in diabetics and creates portals for bacterial entry 5

The Infectious Diseases Society of America suggests that empiric MRSA coverage is generally not necessary for simple paronychia unless specific risk factors are present, such as previous MRSA infection or colonization within the past year, recent hospitalization or healthcare exposure, or local MRSA prevalence >50% among S. aureus isolates 6, 2